Lakefront Biotherapeutics (LKFT)
LKFT trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of October 14, 2026. Revenue: SEC 20-F (ifrs-full:Revenue), period ending 2025-12-31, https://www.sec.gov/Archives/edgar/data/1421876/000110465926035163/0001104659-26-035163-index.htm. Net income: SEC 20-F (ifrs-full:ProfitLossAttributableToOwnersOfParent), period ending 2025-12-31. Converted from EUR at 0.8933 per USD (ECB reference rate).
Profile
| Field | Value |
|---|---|
| Ticker | LKFT on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | Belgium |
| IPO year | 2015 |
| SEC CIK | 0001421876 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | C9 |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $1.2B |
| Net income | $359.2M |
| Operating income | Not in SEC XBRL data |
| Net margin | 28.9% |
| Operating margin | Operating income not reported |
| Revenue growth | No prior-year revenue to compare |
| Cash | Not in SEC XBRL data |
| Total assets | Not in SEC XBRL data |
| P/E (computed) | 5.3× |
| P/S (computed) | 1.5× |
Reported in EUR; shown in US dollars.
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B3 | 2026-05-08 |
| Latest annual report | 20-F | 2026-03-26 |
| Latest quarterly / interim FORM 6-K | 6-K | 2026-10-13 |
Source: SEC EDGAR submissions feed, 541 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -2.5% |
| 1 month | +4.8% |
| 3 months | -1.1% |
| Year to date | -10.5% |
| 1 year | -13.7% |
| From 52-week high | -15.5% |
Source: Yahoo Finance daily closes, last bar 2026-10-14. Computed by Sophia Capital from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| VERA | Vera Therapeutics Inc. | $26.79 | -3.35% | $1.9B |
| SDGR | Schrodinger Inc. | $25.89 | -0.08% | $1.9B |
| ADRX | ADARx Pharmaceuticals Inc. | $17.70 | -1.50% | $1.9B |
| URGN | UroGen Pharma Ltd. | $38.26 | -0.05% | $1.9B |
| XERS | Xeris Biopharma Holdings Inc. | $10.20 | -2.49% | $1.9B |
| MLYS | Mineralys Therapeutics Inc. | $21.00 | -5.53% | $1.9B |
| PVLA | Palvella Therapeutics Inc. | $128.51 | -4.37% | $1.9B |
| AGIO | Agios Pharmaceuticals Inc. | $30.21 | -1.98% | $1.8B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier